Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...

(2021-04-20 | NDAQ:IMNM) Immunome Appoints Corleen Roche as Chief Financial Officer. Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies.

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics ...

Corleen M. Roche's most active month to acquire stocks was the month of December. 2024 saw Corleen M. Roche paying a total of $38,000.00 for 494,920 shares , this is the most they've acquired in ...

I am pleased to welcome Corleen to Iovance at such an important stage in our first commercial launch,” said Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer, President and General ...

Corleen Roche is a corporate finance and business strategist with extensive executive experience in the biopharmaceutical industry. Prior to her most recent role as the U.S. CFO for Biogen, ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.